Major depressive disorder (MDD) is a serious and prevalent illness that continues to be associated with world-leading morbidity and disability as determined by the World Health Organization. Current treatment approaches rely primarily on antidepressant medications and psychotherapy based on clinician's choice, preference, and experience. Studies consistently document that approximately half of patients with moderate-to-severe MDD do not respond adequately to their first medication. Ultimately, current treatment approaches result in a long duration of unremitted illness for many patients, which is associated with worsened long-term prognosis. New interventional treatments are necessary to improve or prevent Treatment Resistant Depressions (TRD).
Speaker: Dr. John Greden
Founder, Frances and Kenneth Eisenberg and Family Depression Center
Rachel Upjohn Professor Emeritus of Psychiatry and Clinical Neurosciences
Research Professor Emeritus, Michigan Neuroscience Institute
Founding Chair, National Network of Depression Centers
Chair Emeritus, University of Michigan Department of Psychiatry
